Back

Low-dose edoxaban in patients 80 years and older with atrial fibrillation and dose-reduction criteria: randomized analysis between edoxaban 15 mg and 30 mg

1 September 2025 (14:05 - 14:15)
Organised by: Logo
Congress Presentation Part of: Management of cardiovascular disease in older adults Cardiovascular Disease in the Elderly ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Andre Zimerman

Hospital Moinhos De Vento, Porto Alegre (Brazil)

4 More presentations in this session

Presentation thumbnail
Clinical outcomes and prognostic implications in super-elderly out-of-hospital cardiac arrest - a multicenter analysis
Associate Professor Y. Lee (Incheon, KR)
Abstract Slides
Presentation thumbnail
Intervention versus conservative treatment for very elderly patients with NSTEMI and frailty: a multi-center observational study
Miss C. Liu (Tianjin, CN)
Abstract Slides
Presentation thumbnail
Impact of frailty on antihypertensive treatment in older adults
Doctor K. Harris (Sydney, AU)
Abstract Slides
Presentation thumbnail
Age-stratified analysis of real-world lipid-lowering therapy use and LDL-C goal attainment at 1-year follow-up: insights from the European SANTORINI study
Professor D. Connolly (Birmingham, GB)
Abstract Slides

Access the full session

Session thumbnail
Management of cardiovascular disease in older adults
Video

The Event

Event poster

ESC Congress 2025

1 September 2025 14:05 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources